EBIT: Income before interest and taxes.
Akari Therapeutics PLC (AKTX) had EBIT of $-7.40M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-6.40M |
|
-- |
|
-- |
|
$7.40M |
|
$-7.40M |
|
$-0.08M |
|
$-7.49M |
|
$-7.49M |
|
$-6.40M |
|
$-6.40M |
|
$-6.40M |
|
$-6.40M |
|
|
EBIT |
$-7.40M |
$-7.40M |
|
32.66M |
|
32.66M |
|
$-0.20 |
|
$-0.20 |
|
| Balance Sheet Financials | |
$2.95M |
|
-- |
|
$42.43M |
|
$45.38M |
|
$15.57M |
|
-- |
|
$7.12M |
|
$22.69M |
|
$22.69M |
|
$-19.74M |
|
$22.69M |
|
32.62M |
|
| Cash Flow Statement Financials | |
$-7.53M |
|
-- |
|
$7.41M |
|
$2.66M |
|
$2.54M |
|
$-0.12M |
|
$2.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.19 |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.53M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-28.21% |
|
32.42% |
|
-14.10% |
|
-28.21% |
|
$0.70 |
|
$-0.23 |
|
$-0.23 |
|